ETTX Insider Trading Activity and SEC Form 4 Filings
ETTX insider trading summary
No open-market insider purchases or sales of Entasis Therapeutics Holdings Inc. (ETTX) have been reported on SEC Form 4 in the past 12 months.
Latest ETTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 11, 2022 | Innoviva Strategic Opportunities LLC | Insider | Buy | $16.7M (7,598,814 @ $2.20) |
| Jul 11, 2022 | Innoviva, Inc. | Insider | Buy | $16.7M (7,598,814 @ $2.20) |
| Jul 8, 2022 | Innoviva Strategic Opportunities LLC | Insider | Buy | $25.7M (11,671,662 @ $2.20) |
| Jul 8, 2022 | Innoviva, Inc. | Insider | Buy | $25.7M (11,671,662 @ $2.20) |
| Oct 19, 2021 | Matthew Ronsheim | See Remarks | Sell | $12K (3,759 @ $3.19) |
| Oct 19, 2021 | John Patrick Mueller | Chief Development Officer | Sell | $13K (4,001 @ $3.19) |
| Oct 19, 2021 | Michael Gutch | See Remarks | Sell | $12K (3,759 @ $3.19) |
| Oct 19, 2021 | Elizabeth M Keiley | General Counsel | Sell | $12K (3,759 @ $3.19) |
| Oct 19, 2021 | David Altarac | Chief Medical Officer | Sell | $12K (3,759 @ $3.19) |
| Oct 19, 2021 | Manoussos Perros | See Remarks | Sell | $38K (11,974 @ $3.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.